LONDON (Reuters) - Bayer (ETR:BAYGN) bowed to investor pressure on Wednesday and named Bill Anderson, most recently head of Roche's pharmaceuticals business, to take over from Werner Baumann as its CEO in June.
Here are some key facts about the career about the 56-year-old American who will run the nearly 160-year-old German drugmaker:
He is a chemical engineer by education and has worked for Genentech and its parent Roche since 2006
CAREER:
1989: started his career at Ethyl Corp, a U.S.-based fuel additives company, with postings in Belgium and the Netherlands
1995: joined Raychem Corp., a U.S. technology and electronics firm
1997-2006: worked at Biogen (NASDAQ:BIIB) in the United States, UK and Ireland; roles included running its neurology unit, its largest business
2006: joined Genentech as senior vice president, immunology and ophthalmology
2010: became svp BioOncology
2013: left Genentech to become global product strategy head/chief marketing officer at Genentech's parent company, Roche
2016: returned to Genentech as head of North American operations
2017: appointed chief executive officer at Genentech
2019-2023: CEO of Roche Pharmaceutical
Sources: Roche and Bayer